Papers using
PCSK9
antibodies
Papers on
PCSK9
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.Krueger et al., Cleveland, United States. In Eur Heart J, Feb 2016
AIMS: The objective of this study was to evaluate the efficacy, safety, and tolerability of LY3015014 (LY), a neutralizing antibody of proprotein convertase subtilisin/kexin type 9 (PCSK9), administered every 4 or 8 weeks in patients with primary hypercholesterolaemia, when added to a background of standard-of-care lipid-lowering therapy, including statins.
[Cholesterol and atherosclerosis. Historical considerations and treatment].Saldívar et al., Mexico. In Arch Cardiol Mex, Feb 2016
Despite, the recognition of historical events for 200 years, starting with Michel Chevreul naming «cholesterol»; later on, Lobstein coining the term atherosclerosis and Marchand introducing it, Anichkov identifying cholesterol in atheromatous plaque, and Brown and Goldstein discovering LDL receptor; as well as the emerging of different drugs, such as fibrates, statins and cetrapibs this decade, promising to increase HDL and the most recent ezetimibe and anti-PCSK9 to inhibit the degradation of LDL receptor, however morbidity has not been reduced in cardiovascular disease.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.ODYSSEY LONG TERM Investigators et al., Chilly-Mazarin, France. In N Engl J Med, May 2015
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators et al., Cape Town, South Africa. In N Engl J Med, May 2015
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies.
Lipids, blood pressure and kidney update 2015.Covic et al., Łódź, Poland. In Lipids Health Dis, 2014
However, for the statin-intolerant patients and those patients requiring essential reductions in LDL-C to achieve their goals, new therapies, including PCSK9 inhibitors remain promising drugs.